The pharmaceutical industry remains one of the sectors of the Russian economy demonstrating double-digit dynamics. According to the 2025 annual report by DSM Group, against the background of overall industrial production growth in the RF of 1.3%, the production volume of medicines and medical materials increased by 15.4%.
In 2024, this figure was also at a high level, at +18%. The industry’s development is refocusing on internal production, as evidenced by investments in new plants and the growing share of Russian drugs in the market.
Target Indicators and Market Share
The total volume of the Russian pharmaceutical market in 2025 reached 3.3 trillion rubles (up 17%), amounting to 5.1 billion packs in physical terms (+3.2%). The actual share of localized drugs exceeded the baseline targets of the “Pharma-2030” strategy and reached 46.8% in value and 69.3% in volume terms.
In the state hospital segment (LPU), Russian-made drugs account for 87.3% of all purchased packs. Meanwhile, in the reimbursed drugs segment (LLO), excluding imported brands localized in the RF, the share of drugs produced within the country stands at 31.4% in rubles (localization of foreign brands adds 6.4% to this figure).
Investments and New Plants
In 2025, Russian and localized companies actively commissioned new high-tech sites. Significant resources were directed at developing the generic segment, creating full-cycle production, and active pharmaceutical ingredient (API) synthesis. Key investment projects in 2025 include:
- Pharm-Sintez in the Kaluga region is investing 16 billion rubles in a full-cycle plant for antitumor drugs.
- Nanolek in the Kirov region invested 7.5 billion rubles in creating production for the first Russian HPV vaccine “Tsegardex”.
- Endopharm in Moscow is investing 5 billion rubles in launching 7 high-tech production lines.
- Artcellens opened the first technological line of a biotechnological R&D center in Moscow.
Innovation Dynamics and Response Measures
The industry faces a decrease in the number of clinical trials (CTs) of innovative drugs from foreign manufacturers. In the first half of 2025, the share of innovative CTs from foreign sponsors fell to 12%, while almost 90% of trials are for generics.
To mitigate the threat to the availability of modern therapies, several tools are used:
- Compulsory licensing: In 2025, licenses for production without patent holder consent were extended for “PSK Pharma” and “Geropharm”.
- Shift in partnership geography: The share of CTs initiated by Indian companies is growing (up to 48.2%), while the share of European companies fell to 19.6%.
- Deep localization: Binnopharm Group and the Chinese company Mabwell plan to localize dupilumab production, and AstraZeneca is moving the output of 5 drugs to the Skopin pharmaceutical plant.
New Rules: Points System and “Second is Odd”
Since January 1, 2026, a points-based system for assessing localization levels has been in effect in Russia. To obtain Russian manufacturer status and access to state support, a drug must score more than 50 points, which are awarded for conducting key production stages within the EAEU.
This status is critical due to the “second is odd” mechanism: if at least one supplier producing a drug in the RF or EAEU via a full cycle (including API synthesis) bids for state tenders, all other applications are rejected. The full launch of this rule for strategically significant medicines (SSMs) is scheduled for July 1, 2026.
